Editorial: Differential Diagnoses of Thyroid Neoplasms: Molecular and Histological Features and the Impact on Follow-up
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
References
1.
Fresilli D, David E, Pacini P, Del Gaudio G, Dolcetti V, Lucarelli G
. Thyroid Nodule Characterization: How to Assess the Malignancy Risk. Update of the Literature. Diagnostics (Basel). 2021; 11(8).
PMC: 8391491.
DOI: 10.3390/diagnostics11081374.
View
2.
Ragusa F, Ferrari S, Elia G, Paparo S, Balestri E, Botrini C
. Combination Strategies Involving Immune Checkpoint Inhibitors and Tyrosine Kinase or BRAF Inhibitors in Aggressive Thyroid Cancer. Int J Mol Sci. 2022; 23(10).
PMC: 9144613.
DOI: 10.3390/ijms23105731.
View
3.
Baldini E, Presutti D, Favoriti P, Santini S, Papoff G, Tuccilli C
. In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic Thyroid Cancer Cell Lines. Int J Mol Sci. 2022; 23(7).
PMC: 8999125.
DOI: 10.3390/ijms23073724.
View
4.
Ohori N
. Molecular testing and thyroid nodule management in North America. Gland Surg. 2020; 9(5):1628-1638.
PMC: 7667110.
DOI: 10.21037/gs-2019-catp-26.
View
5.
Baldini E, Lauro A, Tripodi D, Pironi D, Amabile M, Ferent I
. Thyroid Diseases and Breast Cancer. J Pers Med. 2022; 12(2).
PMC: 8876618.
DOI: 10.3390/jpm12020156.
View